View in EDS HTML Full Text PDF Full Text

Safety and clinical outcomes of pembrolizumab standard-interval dosing versus extended-interval dosing in patients with breast cancer.

Saved in:
Bibliographic Details
Title: Safety and clinical outcomes of pembrolizumab standard-interval dosing versus extended-interval dosing in patients with breast cancer.
Authors: LeVee A; Division of Hematology and Oncology, UCLA Geffen School of Medicine, Los Angeles, CA, USA.; Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Kordic A; Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Ruel N; Department of Biostatistics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Mortimer J; Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Kang I; Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., McArthur H; Division of Hematology and Oncology, UT Southwestern Medical Center, Dallas, TX, USA., Lechner MG; Division of Endocrinology, UCLA Geffen School of Medicine, Los Angeles, CA, USA., Tsai K; Department of Diabetes, Endocrinology and Metabolism, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Source: The oncologist [Oncologist] 2025 Dec 01; Vol. 30 (12).
Publication Type: Journal Article
Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41206668
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Safety and clinical outcomes of pembrolizumab standard-interval dosing versus extended-interval dosing in patients with breast cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22LeVee+A%22">LeVee A</searchLink>; Division of Hematology and Oncology, UCLA Geffen School of Medicine, Los Angeles, CA, USA.; Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.<br /><searchLink fieldCode="AU" term="%22Kordic+A%22">Kordic A</searchLink>; Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.<br /><searchLink fieldCode="AU" term="%22Ruel+N%22">Ruel N</searchLink>; Department of Biostatistics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.<br /><searchLink fieldCode="AU" term="%22Mortimer+J%22">Mortimer J</searchLink>; Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.<br /><searchLink fieldCode="AU" term="%22Kang+I%22">Kang I</searchLink>; Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.<br /><searchLink fieldCode="AU" term="%22McArthur+H%22">McArthur H</searchLink>; Division of Hematology and Oncology, UT Southwestern Medical Center, Dallas, TX, USA.<br /><searchLink fieldCode="AU" term="%22Lechner+MG%22">Lechner MG</searchLink>; Division of Endocrinology, UCLA Geffen School of Medicine, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Tsai+K%22">Tsai K</searchLink>; Department of Diabetes, Endocrinology and Metabolism, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229607837%22">The oncologist</searchLink> [Oncologist] 2025 Dec 01; Vol. 30 (12).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Oxford+University+Press%22">Oxford University Press </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9607837 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1549-490X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210837159%22">10837159 </searchLink><i>NLM ISO Abbreviation: </i>Oncologist <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41206668
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1093/oncolo/oyaf371
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Safety and clinical outcomes of pembrolizumab standard-interval dosing versus extended-interval dosing in patients with breast cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: LeVee A
      – PersonEntity:
          Name:
            NameFull: Kordic A
      – PersonEntity:
          Name:
            NameFull: Ruel N
      – PersonEntity:
          Name:
            NameFull: Mortimer J
      – PersonEntity:
          Name:
            NameFull: Kang I
      – PersonEntity:
          Name:
            NameFull: McArthur H
      – PersonEntity:
          Name:
            NameFull: Lechner MG
      – PersonEntity:
          Name:
            NameFull: Tsai K
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: 2025 Dec 01
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1549-490X
          Numbering:
            – Type: volume
              Value: 30
            – Type: issue
              Value: 12
          Titles:
            – TitleFull: The oncologist
              Type: main
ResultId 1